Novel cancer antigens for personalized immunotherapies

Latest evidence and clinical potential

Gregory T. Wurz, Chiao Jung Kao, Michael W. Degregorio

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The clinical success of monoclonal antibody immune checkpoint modulators such as ipilimumab, which targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the recently approved agents nivolumab and pembrolizumab, which target programmed cell death receptor 1 (PD-1), has stimulated renewed enthusiasm for anticancer immunotherapy, which was heralded by Science as 'Breakthrough of the Year' in 2013. As the potential of cancer immunotherapy has been recognized since the 1890s when William Coley showed that bacterial products could be beneficial in cancer patients, leveraging the immune system in the treatment of cancer is certainly not a new concept; however, earlier attempts to develop effective therapeutic vaccines and antibodies against solid tumors, for example, melanoma, frequently met with failure due in part to self-tolerance and the development of an immunosuppressive tumor microenvironment. Increased knowledge of the mechanisms through which cancer evades the immune system and the identification of tumor-associated antigens (TAAs) and negative immune checkpoint regulators have led to the development of vaccines and monoclonal antibodies targeting specific tumor antigens and immune checkpoints such as CTLA-4 and PD-1. This review first discusses the established targets of currently approved cancer immunotherapies and then focuses on investigational cancer antigens and their clinical potential. Because of the highly heterogeneous nature of tumors, effective anticancer immunotherapy-based treatment regimens will likely require a personalized combination of therapeutic vaccines, antibodies and chemotherapy that fit the specific biology of a patient's disease.

Original languageEnglish (US)
Pages (from-to)4-31
Number of pages28
JournalTherapeutic Advances in Medical Oncology
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Immunotherapy
Antigens
Neoplasms
CTLA-4 Antigen
Neoplasm Antigens
Programmed Cell Death 1 Receptor
Immune System
Vaccines
Monoclonal Antibodies
Combined Vaccines
Self Tolerance
Tumor Microenvironment
Antibodies
Therapeutics
Immunosuppressive Agents
Combination Drug Therapy
Melanoma

Keywords

  • antitumor antibody
  • cancer vaccine
  • cancer-testis antigen
  • immunotherapy
  • oncofetal antigen
  • tumor-associated antigen

ASJC Scopus subject areas

  • Oncology

Cite this

Novel cancer antigens for personalized immunotherapies : Latest evidence and clinical potential. / Wurz, Gregory T.; Kao, Chiao Jung; Degregorio, Michael W.

In: Therapeutic Advances in Medical Oncology, Vol. 8, No. 1, 01.01.2016, p. 4-31.

Research output: Contribution to journalArticle

Wurz, Gregory T. ; Kao, Chiao Jung ; Degregorio, Michael W. / Novel cancer antigens for personalized immunotherapies : Latest evidence and clinical potential. In: Therapeutic Advances in Medical Oncology. 2016 ; Vol. 8, No. 1. pp. 4-31.
@article{12cf88baf4854c1e9d239d8922841aae,
title = "Novel cancer antigens for personalized immunotherapies: Latest evidence and clinical potential",
abstract = "The clinical success of monoclonal antibody immune checkpoint modulators such as ipilimumab, which targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the recently approved agents nivolumab and pembrolizumab, which target programmed cell death receptor 1 (PD-1), has stimulated renewed enthusiasm for anticancer immunotherapy, which was heralded by Science as 'Breakthrough of the Year' in 2013. As the potential of cancer immunotherapy has been recognized since the 1890s when William Coley showed that bacterial products could be beneficial in cancer patients, leveraging the immune system in the treatment of cancer is certainly not a new concept; however, earlier attempts to develop effective therapeutic vaccines and antibodies against solid tumors, for example, melanoma, frequently met with failure due in part to self-tolerance and the development of an immunosuppressive tumor microenvironment. Increased knowledge of the mechanisms through which cancer evades the immune system and the identification of tumor-associated antigens (TAAs) and negative immune checkpoint regulators have led to the development of vaccines and monoclonal antibodies targeting specific tumor antigens and immune checkpoints such as CTLA-4 and PD-1. This review first discusses the established targets of currently approved cancer immunotherapies and then focuses on investigational cancer antigens and their clinical potential. Because of the highly heterogeneous nature of tumors, effective anticancer immunotherapy-based treatment regimens will likely require a personalized combination of therapeutic vaccines, antibodies and chemotherapy that fit the specific biology of a patient's disease.",
keywords = "antitumor antibody, cancer vaccine, cancer-testis antigen, immunotherapy, oncofetal antigen, tumor-associated antigen",
author = "Wurz, {Gregory T.} and Kao, {Chiao Jung} and Degregorio, {Michael W.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1177/1758834015615514",
language = "English (US)",
volume = "8",
pages = "4--31",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Novel cancer antigens for personalized immunotherapies

T2 - Latest evidence and clinical potential

AU - Wurz, Gregory T.

AU - Kao, Chiao Jung

AU - Degregorio, Michael W.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The clinical success of monoclonal antibody immune checkpoint modulators such as ipilimumab, which targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the recently approved agents nivolumab and pembrolizumab, which target programmed cell death receptor 1 (PD-1), has stimulated renewed enthusiasm for anticancer immunotherapy, which was heralded by Science as 'Breakthrough of the Year' in 2013. As the potential of cancer immunotherapy has been recognized since the 1890s when William Coley showed that bacterial products could be beneficial in cancer patients, leveraging the immune system in the treatment of cancer is certainly not a new concept; however, earlier attempts to develop effective therapeutic vaccines and antibodies against solid tumors, for example, melanoma, frequently met with failure due in part to self-tolerance and the development of an immunosuppressive tumor microenvironment. Increased knowledge of the mechanisms through which cancer evades the immune system and the identification of tumor-associated antigens (TAAs) and negative immune checkpoint regulators have led to the development of vaccines and monoclonal antibodies targeting specific tumor antigens and immune checkpoints such as CTLA-4 and PD-1. This review first discusses the established targets of currently approved cancer immunotherapies and then focuses on investigational cancer antigens and their clinical potential. Because of the highly heterogeneous nature of tumors, effective anticancer immunotherapy-based treatment regimens will likely require a personalized combination of therapeutic vaccines, antibodies and chemotherapy that fit the specific biology of a patient's disease.

AB - The clinical success of monoclonal antibody immune checkpoint modulators such as ipilimumab, which targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the recently approved agents nivolumab and pembrolizumab, which target programmed cell death receptor 1 (PD-1), has stimulated renewed enthusiasm for anticancer immunotherapy, which was heralded by Science as 'Breakthrough of the Year' in 2013. As the potential of cancer immunotherapy has been recognized since the 1890s when William Coley showed that bacterial products could be beneficial in cancer patients, leveraging the immune system in the treatment of cancer is certainly not a new concept; however, earlier attempts to develop effective therapeutic vaccines and antibodies against solid tumors, for example, melanoma, frequently met with failure due in part to self-tolerance and the development of an immunosuppressive tumor microenvironment. Increased knowledge of the mechanisms through which cancer evades the immune system and the identification of tumor-associated antigens (TAAs) and negative immune checkpoint regulators have led to the development of vaccines and monoclonal antibodies targeting specific tumor antigens and immune checkpoints such as CTLA-4 and PD-1. This review first discusses the established targets of currently approved cancer immunotherapies and then focuses on investigational cancer antigens and their clinical potential. Because of the highly heterogeneous nature of tumors, effective anticancer immunotherapy-based treatment regimens will likely require a personalized combination of therapeutic vaccines, antibodies and chemotherapy that fit the specific biology of a patient's disease.

KW - antitumor antibody

KW - cancer vaccine

KW - cancer-testis antigen

KW - immunotherapy

KW - oncofetal antigen

KW - tumor-associated antigen

UR - http://www.scopus.com/inward/record.url?scp=84951790085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951790085&partnerID=8YFLogxK

U2 - 10.1177/1758834015615514

DO - 10.1177/1758834015615514

M3 - Article

VL - 8

SP - 4

EP - 31

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 1

ER -